EN | SE Contact us
1907 About Transl

BioInvent - translating cancer antibody biology into innovative immuno-oncology therapies.

BioInvent's current operational activities are focused on:

  • Progressing and expanding the clinical development of its lead antibody BI-1206 for treatment of NHL, and in combination with pembrolizumab (KEYTRUDA®) in advanced solid cancers.
  • Developing preclinical first-in-class antibodies targeting tumor associated myeloid cells in collaboration with Pfizer, potential other partners, or alone.
  • Advancing three compounds into clinical programs:
    • BI-1808, the Company’s most advanced anti-TNFR2 antibody, as a single agent and in combination with an anti-PD1 antibody. A clinical trial application was submitted in June 2020.
    • BI-1607 (an anti-FcγRIIB antibody) in combination with a checkpoint inhibitor. A clinical trial application is expected to be submitted in Q1 2021.
    • Developing, in combination with Transgene, oncolytic viruses encoding either a proprietary anti-CTLA-4 antibody sequence, or antibody sequences targeting undisclosed targets for the treatment of solid tumors. BT-001, an anti-CTLA-4/oncolytic virus – a clinical trial application was submitted in Q1 2020.

Immuno-oncology drugs can revolutionise treatment of cancer

The body’s immune system detects and destroys bacteria and viruses that would otherwise harm our organs and tissues. However, the immune system also has the potential to protect us from and fight cancer. Unfortunately, many tumour cells have the ability to manipulate important cells in our immune system in order to continue to multiply.

While chemotherapy is aimed directly at the tumour cells, immuno-oncology drugs activate important cells in the immune system (especially T-cells), and stimulate them to attack tumours. Immuno-oncology drugs are one of the greatest breakthroughs of the twenty-first century in the field of medicine.

They are making an important contribution in transforming the treatment of cancer through significant improvements in survival rates. However currently available immune modulatory drugs are only able to help a fraction of all cancer patients.

The global immuno-oncology market is expected to reach USD 76 bn by 2022, according to Global Immuno-Oncology Market Demand Analysis /Opportunity evaluation 2019-2027. Nov 2019 and Global data market analysis 2018.

1907 About Checkpoint


BioInvent’s primary goal is to develop next generation immuno-oncological drugs with a focus on improving therapeutic results in areas with significant unmet need.


BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.

Business model

BioInvent has three main areas for commercialization. The Company's primary value drivers are clinical and preclinical development projects. BioInvent also has research and development collaborations based on the Company's technology platform F.I.R.S.TTM and n-CoDeR®. BioInvent’s manufacturing facility provides capacity to produce antibodies for the Company’s preclinical studies and clinical trials, which is mandatory for a swift preclinical/clinical development path. The manufacturing facility provides also the opportunity to manufacture antibodies to external parties.